Objectives: Cervical cancer screening test performance has been hampered by either a lack of sensitivity in Pap cytology or a lack of specificity of human papillomavirus (HPV) testing. This is disturbing for patients and a cause of high costs for health care providers. Study Design: The identification of p16INK4a as a specific marker for the neoplastic transformation of cervical squamous epithelial cells by HPVs allows the identification of HPV-transformed cells in cytopathology specimens. Results: When compared to molecular HPV tests for triaging minor cytologic atypia, such as atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesions, the immunochemical detection of dual p16INK4a/Ki-67-stained cells demonstrates a significantly improved specificity with good relative sensitivity. Conclusions: HPV testing has shown earlier detection of persistent high-grade squamous intraepithelial lesions (HSIL) compared to cytology and is more effective in preventing invasive cervical cancer. The next challenge for the HPV primary screening program is to find the best method(s) for selecting, among HPV-positive women, those patients in need of immediate colposcopy because they are at a higher risk of developing a precancerous lesion. An HSIL cytology result and/or dual p16/Ki-67 staining could be the best candidates, but further randomized studies are required before these approaches can be used in routine practice.

Keywords:
Cervical cancer, Cytology, p16INK4a/Ki-67, Human papillomavirus, Screening
1.
Bergeron C, Ronco G, Reuschenbach M, Wentzensen N, Arbyn M, Stoler M, von Knebel Doeberitz M: The clinical impact of using p16INK4a immunochemistry in cervical histopathology and cytology: an update of recent developments. Int J Cancer 2014;136:2741-2751.
2.
Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al: The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012;16:205-242.
3.
Stoler M, Bergeron C, Colgan TJ, Ferenczy A, Herrington CS, Loening T, et al: Squamous cell tumors and precursors; in Kurman RJ, Carcangiu ML, Herrington CS, Young CS (eds): WHO Classification of Tumours of Female Reproductive Organs. Lyon, IARC, 2014, chapt 7, pp 1-12.
4.
Reuschenbach M, Seiz M, von Knebel Doeberitz C, Vinokurova S, Duwe A, Ridder R, Sartor H, Kommoss F, Schmidt D, von Knebel Doeberitz M: Evaluation of cervical cone biopsies for coexpression of p16INK4a and Ki-67 in epithelial cells. Int J Cancer 2012; 130:388-394.
5.
Schmidt D, Bergeron C, Denton KJ, Ridder R: p16/Ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011;119:158-166.
6.
Waldstrøm M, Kølby Christensen R, Ørnskov D: Evaluation of p16INK4a/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion. Cancer Cytopathol 2013;121:136-145.
7.
Ziemke P, Marquardt K, Griesser H: Predictive value of the combined p16INK4a and Ki-67 immunocytochemistry in low-grade squamous intraepithelial lesions. Acta Cytol 2014;58:489-494.
8.
Bergeron C, Ikenberg H, Sideri M, Denton K, Bogers J, Schmidt D, et al: Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol 2015;123:373-381.
9.
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al: Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-532.
10.
Ronco G, Arbyn M, Meijer CJLM, Snijders PJF, Cuzick J: S1 screening for cervical cancer with primary testing for human papillomavirus; in Anttila A, Arbyn M, de Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E, Tornberg S, von Karsa L (eds): Supplements to European Guidelines for Quality Assurance in Cervical Cancer Screening, ed 2 - Supplements. Luxembourg, European Commission, 2015.
11.
Bergeron C, Giorgi-Rossi P, Cas F, Schiboni ML, Ghiringhello B, Dalla Palma P, et al: Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst 2015;107:dju423.
12.
Carozzi F, Gillio-Tos A, Confortini M, del Mistro A, Sani C, De Marco L, et al: Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013;14:168-176.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.